手术后^(131)I联合优甲乐治疗分化型甲状腺癌的临床研究  

Clinical Study on Treatment of Differentiated Thyroid Carcinoma with ^(131)I Combined with Euthyrox after Operation

作　　者：黄浩[1] 黄治文 邱坤辉 黄勇波[1] HUANG Hao;HUANG Zhiwen;QIU Kunhui(Central People’s Hospital of Zhanjiang,Zhanjiang 524045,Chin)

机构地区：[1]广东省湛江中心人民医院,广东湛江524045 [2]广东省湛江麻章甲状腺专科医院

出　　处：《中国医学创新》2018年第11期100-103,共4页Medical Innovation of China

基　　金：湛江市第二批非资助科技攻关计划项目(2017B01069)

摘　　要：目的:观察手术后^(131)I联合优甲乐治疗分化型甲状腺癌的临床效果。方法:选择2015年6月-2017年6月在湛江中心人民医院及湛江麻章甲状腺专科医院收治的分化型甲状腺癌中高危患者120例进行研究,按照随机数字表法分为观察组和对照组,各60例。对照组术后常规给予优甲乐治疗,观察组在对照组治疗基础上给予^(131)I治疗。观察两组术后Tg水平、颈部超声、诊断性全身扫描情况。结果:治疗前,两组Tg水平比较,差异无统计学意义(P>0.05);治疗后,两组Tg水平均明显低于治疗前,差异均有统计学意义(P<0.05);观察组Tg水平明显低于对照组,差异有统计学意义(P<0.05)。观察组残余甲状腺组织去除率为78.33%,明显高于对照组的58.33%,差异有统计学意义(P<0.05)。观察组患者肿瘤对治疗反应良好率为70%(42/60)明显高于对照组的50%(30/60),差异有统计学意义(x^2=4.201,P=0.040)。观察组不良反应发生率为3.33%,虽略高于对照组的1.67%,但差异无统计学意义(P>0.05)。结论:分化型甲状腺癌患者术后给予^(131)I联合优甲乐治疗具有良好的临床效果,能够明显增加参与甲状腺清除率,使肿瘤对治疗反应良好率提升。Objective：To observe the clinical efficacy of ^131I combined with Euthyrox after operation in the treatment of differentiated thyroid carcinoma.Method：A total of 120 differentiated thyroid carcinoma high risk patients in Central People＇s Hospital of Zhanjiang and Mazhang Thyroid Specialist Hospital of Zhanjiang from June 2015 to June 2017 were selected and divided into the observation group and the control group according to table of random numbers,60 cases in each group.The control group was given the routine treatment after operation,and the observation group was treated with ^131I on the basis of the control group.The Tg level,neck ultrasound and diagnostic general scan were observed in the two groups.Result：Before treatment,Tg levels of the two groups were not significant differences（P〈0.05）;after treatment,Tg levels of the two groups were lower than those before treatment（P〈0.05）;and the Tg level of the observation group was significantly lower than that of the control group（P〈0.05）.The residual thyroid tissue removal rate of the observation group was 78.33%,which was higher than 58.33% of the control group（P〈0.05）.The positive rate of tumor response to treatment in the observation group was 70%（42/60）,which was significantly higher than 50%（30/60） in the control group,the difference was statistically significant（ x^2=4.201,P=0.040）.The incidence of adverse reactions in the observation group was 3.33%,which was slightly higher than 1.67% in the control group,but the difference was not statistically significant（P〉0.05）.Conclusion：The treatment of differentiated thyroid cancer patients with ^131I combined with Euthyrox has good clinical effect,it can significantly increase the participation rate of thyroid clearance and improve the rate of tumor response to treatment.

关 键 词：^131I 优甲乐 分化型 甲状腺癌 

分 类 号：R736.1[医药卫生—肿瘤]